

Supplementary data

Supplementary Appendix 1. Methods: **inclusion and exclusion criteria.**

Inclusion criteria

1. Age \geq 18 years
2. History of diabetes mellitus with any indication for angiography (stable angina or any type of acute coronary syndrome including ST-elevation MI).
3. Coronary angiography, including FFR and OCT imaging of at least one coronary de novo stenosis in a native not-grafted vessel with a visually estimated diameter stenosis of $\geq 40 - \leq 80\%$ (target lesion)¹. Target lesion should be other than the culprit lesion(s) in patients presenting with myocardial infarction (ST-elevation myocardial infarction or non-ST-elevation myocardial infarction).

Exclusion criteria

1. TIMI flow < 3 in the target lesion(s)
2. Target lesion reference diameter (on visual estimation) < 2.0 mm
3. Known left ventricular ejection fraction $< 30\%$
4. Known malignancy
5. Life expectancy < 2 years
6. Unwilling or unable to provide informed consent

Supplementary Table 1. Medications at discharge, at 18-month follow-up, and up to 5-year follow-up.

Variables	FFR(-)/TCFA(+)	FFR(-)/TCFA(-)	p Value
Medications at discharge	n=98	n=292	
Aspirin	87 (88.78%)	250 (85.62%)	0.50
P2Y12 antagonist	61 (62.24%)	132 (45.21%)	<0.001
Anticoagulation	18 (18.37%)	56 (19.18%)	0.99
ACE inhibitor	43 (43.88%)	136 (46.58%)	0.73
ARB	18 (18.37%)	76 (26.03%)	0.14
Betablockers	80 (81.63%)	211 (72.26%)	0.08
Calcium antagonist	32 (32.65%)	99 (33.90%)	0.90
Digoxin	3 (3.06%)	6 (2.05%)	0.70
Diuretics	34 (34.69%)	117 (40.07%)	0.40
Insulin	38 (38.78%)	103 (35.27%)	0.55
Oral anti-diabetic	80 (81.63%)	226 (77.40%)	0.48
Statin	74 (75.51%)	249 (85.27%)	0.031
Medications at 18-month follow-up	n=98	n=292	
Aspirin	70 (71.43%)	197 (67.47%)	0.53
P2Y12 antagonist	24 (24.49%)	39 (13.36%)	0.017
Anticoagulation	17 (17.35%)	59 (20.21%)	0.66
ACE inhibitor	47 (47.96%)	117 (40.07%)	0.19
ARB	20 (20.41%)	68 (23.29%)	0.68
Betablockers	68 (69.39%)	189 (64.73%)	0.46
Calcium antagonist	25 (25.51%)	80 (27.40%)	0.79
Digoxin	4 (4.08%)	6 (2.05%)	0.28
Diuretics	31 (31.63%)	103 (35.27%)	0.54
Insulin	38 (38.78%)	99 (33.90%)	0.39
Oral anti-diabetic	66 (67.35%)	213 (72.95%)	0.30
Statin	63 (64.29%)	221 (75.68%)	0.036
Medications up to 5-year follow up	n=91	n=278	
Aspirin	64 (70.33%)	173 (62.23%)	0.17
P2Y12 antagonist	18 (19.78%)	32 (11.51%)	0.053
Anticoagulation	20 (21.98%)	59 (21.22%)	0.88
ACE inhibitor	36 (39.56%)	113 (40.65%)	0.90
ARB	15 (16.48%)	61 (21.94%)	0.30
Betablockers	61 (67.03%)	176 (63.31%)	0.61
Calcium antagonist	29 (31.87%)	88 (31.65%)	0.99
Digoxin	4 (4.40%)	7 (2.52%)	0.48
Diuretics	26 (28.57%)	85 (30.58%)	0.79
Insulin	35 (38.46%)	85 (30.58%)	0.20
Oral anti-diabetic	64 (70.33%)	204 (73.38%)	0.59
Statin	60 (65.93%)	205 (73.74%)	0.18

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker, FFR, fractional flow reserve; TCFA, thin-cap fibroatheroma